X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dr. Reddys with Pfizer - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs PFIZER - Comparison Results

DR. REDDYS LAB    Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

PFIZER 
   Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. REDDYS LAB PFIZER DR. REDDYS LAB/
PFIZER
 
P/E (TTM) x 26.1 34.6 75.3% View Chart
P/BV x 3.6 5.5 66.2% View Chart
Dividend Yield % 0.7 0.6 116.7%  

Financials

 DR. REDDYS LAB   PFIZER
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-18
PFIZER
Mar-18
DR. REDDYS LAB/
PFIZER
5-Yr Chart
Click to enlarge
High Rs2,7882,365 117.9%   
Low Rs1,9021,625 117.0%   
Sales per share (Unadj.) Rs860.8430.3 200.1%  
Earnings per share (Unadj.) Rs57.178.7 72.5%  
Cash flow per share (Unadj.) Rs122.093.2 130.9%  
Dividends per share (Unadj.) Rs20.0020.00 100.0%  
Dividend yield (eoy) %0.91.0 85.1%  
Book value per share (Unadj.) Rs757.7586.5 129.2%  
Shares outstanding (eoy) m165.9145.75 362.6%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.74.6 58.8%   
Avg P/E ratio x41.125.3 162.1%  
P/CF ratio (eoy) x19.221.4 89.8%  
Price / Book Value ratio x3.13.4 91.0%  
Dividend payout %35.025.4 137.9%   
Avg Mkt Cap Rs m389,03491,271 426.2%   
No. of employees `00023.52.6 894.4%   
Total wages/salary Rs m32,1493,143 1,022.9%   
Avg. sales/employee Rs Th6,070.87,484.8 81.1%   
Avg. wages/employee Rs Th1,366.61,195.0 114.4%   
Avg. net profit/employee Rs Th402.51,369.1 29.4%   
INCOME DATA
Net Sales Rs m142,81019,685 725.5%  
Other income Rs m1,5521,143 135.8%   
Total revenues Rs m144,36220,828 693.1%   
Gross profit Rs m23,5125,003 470.0%  
Depreciation Rs m10,772663 1,626.0%   
Interest Rs m7884 18,761.9%   
Profit before tax Rs m13,5045,479 246.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m3440-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m4,3801,878 233.2%   
Profit after tax Rs m9,4683,601 262.9%  
Gross profit margin %16.525.4 64.8%  
Effective tax rate %32.434.3 94.6%   
Net profit margin %6.618.3 36.2%  
BALANCE SHEET DATA
Current assets Rs m104,98424,167 434.4%   
Current liabilities Rs m68,9389,544 722.3%   
Net working cap to sales %25.274.3 34.0%  
Current ratio x1.52.5 60.1%  
Inventory Days Days7455 135.0%  
Debtors Days Days10429 360.9%  
Net fixed assets Rs m104,3859,514 1,097.2%   
Share capital Rs m830458 181.4%   
"Free" reserves Rs m124,88626,375 473.5%   
Net worth Rs m125,71626,832 468.5%   
Long term debt Rs m25,08925 100,356.0%   
Total assets Rs m225,44336,900 611.0%  
Interest coverage x18.11,305.5 1.4%   
Debt to equity ratio x0.20 21,419.3%  
Sales to assets ratio x0.60.5 118.7%   
Return on assets %4.59.8 46.6%  
Return on equity %7.513.4 56.1%  
Return on capital %9.720.4 47.5%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m72,62322 324,209.8%   
Fx outflow Rs m18,9161,489 1,270.6%   
Net fx Rs m53,707-1,466 -3,662.8%   
CASH FLOW
From Operations Rs m18,0303,318 543.4%  
From Investments Rs m-14,883-2,383 624.5%  
From Financial Activity Rs m-4,440-1,104 402.4%  
Net Cashflow Rs m-1,236-169 733.5%  

Share Holding

Indian Promoters % 25.5 0.0 -  
Foreign collaborators % 0.0 63.9 -  
Indian inst/Mut Fund % 5.4 7.5 72.0%  
FIIs % 35.3 4.9 720.4%  
ADR/GDR % 18.5 0.0 -  
Free float % 15.3 23.7 64.6%  
Shareholders   75,885 85,207 89.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. REDDYS LAB With:   SUN PHARMA  WYETH LTD  ABBOTT INDIA  FULFORD INDIA  MERCK  

Compare DR. REDDYS LAB With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Marginally Higher; Realty and IT Stocks Witness Buying(Closing)

Indian share markets witnessed volatility during closing hours and ended their day marginally higher. Gains were largely seen in the realty sector and IT sector.

Related Views on News

DR. REDDYS LAB Announces Quarterly Results (3QFY19); Net Profit Up 67.0% (Quarterly Result Update)

Feb 4, 2019 | Updated on Feb 4, 2019

For the quarter ended December 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 67.0% YoY). Sales on the other hand came in at Rs 39 bn (up 0.8% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.

PFIZER Announces Quarterly Results (3QFY19); Net Profit Up 51.2% (Quarterly Result Update)

Jan 25, 2019 | Updated on Jan 25, 2019

For the quarter ended December 2018, PFIZER has posted a net profit of Rs 1 bn (up 51.2% YoY). Sales on the other hand came in at Rs 5 bn (up 12.5% YoY). Read on for a complete analysis of PFIZER's quarterly results.

PFIZER 2017-18 Annual Report Analysis (Annual Result Update)

Jan 1, 2019 | Updated on Jan 1, 2019

Here's an analysis of the annual report of PFIZER for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PFIZER. Also includes updates on the valuation of PFIZER.

PFIZER Announces Quarterly Results (2QFY19); Net Profit Down 13.8% (Quarterly Result Update)

Nov 15, 2018 | Updated on Nov 15, 2018

For the quarter ended September 2018, PFIZER has posted a net profit of Rs 958 m (down 13.8% YoY). Sales on the other hand came in at Rs 5 bn (down 9.0% YoY). Read on for a complete analysis of PFIZER's quarterly results.

PFIZER Announces Quarterly Results (1QFY19); Net Profit Up 60.6% (Quarterly Result Update)

Aug 3, 2018 | Updated on Aug 3, 2018

For the quarter ended June 2018, PFIZER has posted a net profit of Rs 918 m (up 60.6% YoY). Sales on the other hand came in at Rs 5 bn (up 18.4% YoY). Read on for a complete analysis of PFIZER's quarterly results.

More Views on News

Most Popular

Are You Ready for the Big Nifty Move in the March Expiry?(Profit Hunter)

Mar 8, 2019

History suggests the Nifty could make a big move in March. Are you prepared to benefit from this opportunity?

5 Fundamentally Strong Stocks to Pick for Trading Today(Profit Hunter)

Mar 15, 2019

5 fundamentally strong stocks one could buy to trade in this market right now. Make sure you grab the chance this strongly rallying market offers.

Elections Don't Matter!(The Honest Truth)

Mar 13, 2019

Ajit Dayal shows us why from the point of view of the Indian economy, elections don't matter.

Two Growth Stocks that Doubled in a Little Over 12 Months!(The 5 Minute Wrapup)

Mar 13, 2019

The elements that fueled profit growth for these two companies led to a surge in their stock prices.

This is Why You Need to Buy Small Cap Stocks Now(The 5 Minute Wrapup)

Mar 15, 2019

Did you just miss the smallcap rally? Or is there still time to catch up? Read on for answers and more...

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Mar 20, 2019 (Close)

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB - STERLING BIOTECH COMPARISON

COMPARE DR. REDDYS LAB WITH

MARKET STATS